News

According to the deal, Cellmid will receive initial fee besides additional payment if Fujikura decides on exercising its license option. Upon any future sales of midkine diagnostic products

The patent entitled, ‘Abuse-Deterrent Drug Formulation’, covers Oxycodone DETERx (COL-003) product which utilizes the company’s proprietary DETERx drug delivery technology. Currently in the final stage of clinical development,

The application covers a drug delivery system based on the company’s Smart Surface technology, which electronically or manually controls the dispensing of a fluid on a nano-structured surface.

Mesoblast will supply MPCs manufactured at Singapore manufacturing facility of its contract manufacturer, Lonza, besides at its US facility. Mesoblast chief executive Professor Silviu Itescu said, "Having multiple

The progression of the compound into pre-clinical development has triggered a milestone payment to Evotec from Ono, as per the deal signed between the companies in March 2008.

As per the deal, RQx will earn an up-front payment in addition to research and development milestone payments worth $111m. RQx CEO and venture partner at Avalon Venture

The collaboration will focus on developing small-molecule therapies directed to select new targets to treat autoimmune diseases. Lycera president and chief executive officer Kathleen Metters said, "Lycera’s proven

Sobi gained distribution rights in Ireland, United Kingdom, France, Italy, Germany, Spain, Finland, Sweden, Denmark, Norway, Austria, Belgium, Liechtenstein, Netherlands, Portugal, and Luxembourg. The distribution is expected to

Agilent’s commercial products include RapidFire system, designed for use in pharmaceutical and biopharmaceutical laboratories. Agilent RapidFire business director Can Ozbal said, "By using multiple RapidFire systems Ameritox is